Recombinant human serum albumin

Human serum albumin is the most abundant protein in plasma. A single 585-residue chain folded into three homologous domains and cross-linked by seventeen disulfide bonds, it is unusually robust — and it performs two functions that have nothing in common.

Holding water in the vessels

Capillary walls are permeable to water and small solutes but not to proteins. Plasma proteins are therefore trapped inside the vessel and exert an osmotic pull that opposes the hydrostatic pressure driving fluid out — colloid osmotic pressure, or oncotic pressure.

Albumin supplies the great majority of it, both because it is the most abundant plasma protein and because it is comparatively small, so it contributes more particles per gram than larger proteins. Its net negative charge adds further to the effect by retaining counter-ions.

This is the mechanism behind its clinical use. In hypoalbuminaemia, fluid leaves the circulation into the interstitium, producing oedema and ascites; infused albumin restores the gradient. It is also why the concentration of the solution matters: a 4–5 percent solution is roughly iso-oncotic and expands volume by about what is given, while a 20–25 percent solution is hyper-oncotic and draws additional fluid in from the tissues.

Carrying almost everything

Albumin’s second role is transport, and it is remarkably unselective. Two well-characterised regions — conventionally Sudlow sites I and II — are flexible hydrophobic pockets that accommodate a wide range of ligands: fatty acids, bilirubin, bile acids, hormones, metal ions, and a large fraction of clinically used drugs.

This promiscuity has direct consequences. Only the unbound fraction of a drug is pharmacologically active and available for clearance, so a fall in albumin raises the free fraction of a highly bound drug at unchanged total concentration. Drugs competing for the same site displace one another. And albumin’s fatty-acid binding is what keeps otherwise insoluble lipids in circulation at all.

The same promiscuity is why albumin is used far outside medicine — as a stabiliser in vaccines and protein formulations, as a blocking agent in assays, and as a component of cell culture media, where a recombinant source removes the animal-origin question.

Why the recombinant route is difficult

Two things make it hard, and neither is expression level.

Folding. Seventeen disulfide bonds must form in the correct pairing. Mispaired bonds give misfolded or aggregated protein, so the host must have oxidative folding machinery capable of handling it — which is why secretory yeasts such as Komagataella are used, exporting the protein through a compartment equipped for disulfide formation.

Dose scale. This is the constraint that distinguishes albumin from most recombinant proteins. A therapeutic antibody is dosed in milligrams; albumin is dosed in grams — a 100 mL bottle of 20 percent solution contains 20 g of protein. An impurity at one part per million is therefore delivered in tens of micrograms per dose, and host-cell proteins, host DNA and endotoxin all have to be controlled to levels that would be unremarkable at milligram scale and are demanding at this one.

The motivation is supply and safety: plasma-derived albumin depends on donation and carries the residual viral-transmission concerns that attach to any blood product, both of which a recombinant source removes.